Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
mild nausea or reduced appetite may occur within the first few hours
(2022) 20:194203.e1
Key results: On-treatment (no interruptions): Semaglutide (Wegovy): 57% lower risk of heart attack, stroke, or death Tirzepatide: Reference comparator Including treatment gaps: Semaglutide: 29% lower risk of major adverse cardiovascular events Tirzepatide: Higher event rates in this real-world analysis Why this matters: These data suggest semaglutide may have greater cardiovascular benefit than tirzepatidea provocative finding given both are highly effective for weight loss
2023 Rosenstock, Julio et al
US$ 26.56
US$ 29.68
US$ 21.72
US$ 21.68
US$ 25.82
US$ 23.09
US$ 27.83
US$ 28.20
US$ 23.85
